Lv7
4960 积分 2022-08-15 加入
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
15小时前
待确认
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML
15小时前
待确认
Maintenance Therapy in Acute Myeloid Leukemia
15小时前
待确认
FLT3 mutations as diagnostic and prognostic biomarkers in acute myeloid leukemia
4天前
已完结
The global epidemiology of acute myeloid leukaemia
18天前
已完结
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
29天前
已完结
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party
29天前
已完结
Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
